Here's why the Opthea (ASX:OPT) share price is soaring 8%

This biopharmaceutical company is developing therapies to treat progressive retinal diseases.

| More on:
A woman sits inside a cubicle undergoing an eyetest

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Opthea Ltd (ASX: OPT) share price is soaring today, up more than 8% trading at $1.37 at the time of writing.

The clinical stage biopharmaceutical company is focused on developing therapies to treat progressive retinal diseases.

Below, we look at the company's latest update from its United States' endeavours.

What update did Opthea announce?

Opthea's share price is rocketing after the company reported that it had received Fast Track designation from the US Food and Drug Administration (FDA) for its product to treat patients with neovascular (wet) age-related macular degeneration (AMD).

Opthea said the Fast Track designation for its VEGF-C/-D 'trap' inhibitor, OPT-302, used in combination with anti-VEGF-A therapy, recognises the potential role that OPT-302 has for addressing significant unmet needs to manage neovascular AMD.

The FDA's Fast Track designation opens the door to Opthea for improved communications with the administration. It said a rolling review process enabled by the designation will help speed up its Phase 3 development program and approval review processes.

It noted that OPT-302 may now also be eligible for accelerated approval and priority review as long as it meets the needed criteria.

Commenting on the Fast Track approval, Opthea's CEO Megan Baldwin said:

The recognition from the FDA to grant OPT-302 Fast Track designation reflects the seriousness of wet AMD as a debilitating eye disease and the importance of advancing new therapies such as OPT-302 to address the significant unmet medical need for wet AMD patients, many of whom experience an incomplete response to VEGF-A inhibitors despite regular, ongoing therapy.

By targeting a novel mechanism of action, OPT-302 has the potential to be a truly differentiated treatment option that when used in combination offers patients improved vision outcomes over standard of care anti-VEGF-A monotherapy.

Opthea said it was currently recruiting patients for 2 simultaneous global Phase 3 trials, with some 990 patients expected in each.

Opthea share price snapshot

Despite today's rise, the Opthea share price remains down 45% over the past 12 months, during a period that saw the All Ordinaries Index (ASX: XAO) gain 24%.

Year-to-date, the Opthea share price has remained under pressure, down 30%.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »